Leerink Swann assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued an outperform rating and a $10.00 target price on the biopharmaceutical company’s stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.